Loading...
OTCM
CLLKF
Market cap92mUSD
Jul 07, Last price  
1.58USD
1Q
-17.06%
IPO
-85.66%
Name

BICO Group AB

Chart & Performance

D1W1MN
OTCM:CLLKF chart
P/E
P/S
0.70
EPS
Div Yield, %
Shrs. gr., 5y
10.81%
Rev. gr., 5y
53.31%
Revenues
1.50b
-23.07%
013,188,00045,337,000105,457,000176,793,0001,257,300,0002,239,500,0002,010,400,0001,946,300,0001,497,200,000
Net income
-1.09b
L+19,698.18%
0155,0001,183,000581,000-61,888,000-229,200,000-835,700,000-1,172,700,000-5,500,000-1,088,900,000
CFO
68m
-56.82%
-2,021,143-179,000-12,263,000-15,818,000-71,817,000-409,200,000-269,400,000178,400,000158,400,00068,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BICO Group AB (publ) is a global bio-convergence enterprise, conducting operations across North America, Europe, Asia, and other international markets. Its business is structured into two main divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment delivers a range of advanced equipment, including 3D bioprinters, hybrid microscopy systems, single-cell dispensing instruments, and liquid handling devices. This division also supplies essential consumables such as bioinks, reagents, microscope lenses, software, printheads, and even 3D reconstructed human tissues, particularly for applications in regulatory testing. Furthermore, Laboratory Solutions offers specialized services like 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology, primarily serving pharmaceutical and biotechnology companies. Conversely, the Bioautomation segment caters to industrial customers with products focused on precision dispensing and innovative biosensor technology. It also provides sophisticated diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. Overall, BICO Group's offerings include comprehensive solutions for industrial ecosystems, tissue engineering, multi-omics analysis, cell line development, and diagnostics. Its primary clientele originates from the medical, pharmaceutical, and cosmetic sectors. Founded in 2016 and headquartered in Gothenburg, Sweden, the company was previously known as Cellink AB (publ) before officially changing its name to BICO Group AB (publ) in August 2021.
IPO date
Nov 03, 2016
Employees
1,069
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑082019‑082018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT